

Examiner's | Cite No.

NFORMATION DISCLOSURE STATEMENT LIST

Complete if Known Application Number 10/517,898 Filing Date 14 June 2002 First Named Inventor Warren Strober Group Art Unit 2123 Examiner Name Unassigned

(Use as many sheets as necessary)

U.S. PATENT DOGUMENTS									
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate		
							-		
							1		
							-		

FOREIGN PATENT DOCUMENTS

Examiner's	Cite No.	Foreign Patent	Date	Name	Translation
Initials		Document	ŀ		' Yes/No
		Country Code-Number- Kind Code			
	C1	WO 03/080675	2 Oct 2003	Dunlop et al.	Υ
	C2	WO 01/82960	8 Nov 2001	Zeng, D.	Υ
	C3	WO 00/64944	2 Nov 2000	Gyure, B	Υ
		N	ON-PATENT P	OCHMENTS	

Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Pu

Initials		
	C4	Bost et al. "In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice" Immunol. 87:633-64 (1996)
	C5	Chiaramonte et al. "IL-13 is a key regulator cytokine for Th2 cell-mediated pulmonary granuloma rormation and Igt responses induced by <i>S. mansoni</i> eggs". <i>J. Immunol.</i> 162(2):920-930 (1999)
	C6	Grünig et al. "Requirement for IL-13 independently of IL-4 in experimental asthma" Science 282:2261-2263 (18 Dec 1998)
	C7*	Hans et al. "Interleukin 12 induced interferon-y increases inflammation in acute dextran sulfate sodium induced colitis in mice" Eur. Cytokine Netw 11:67-74 (March 2000)
	C8*	Shalaby et al. "In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and interleukin-2". J Interferon Research 5:571-581 (1985)
	C9	Verdú et al. "Modulatory effects of estrogen in two murine models of experimental colitis" Am J Physiol Gastrointest Liver Physiol 283:G27-G36 (2002)

Examiner Signature: /Ilia Ouspenski/ | Date Considered:

01/02/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.